|
Synonyms: GSK'227 | GSK5764227 | HS-20093 | Ris-Rez
Compound class:
Antibody
Comment: Risvutatug rezetecan (GSK5764227, formerly HS-20093; Ris-Rez) is an antibody-drug congugate that targets a camptothecin derived topoisomerase I inhibitor to (tumour) cells expressing CD276 (B7-H3) [2-3,5]. Peptide sequences for risvutatug's heavy and light chains are claimed in Hansoh patent US10899837B2, and these form the antibody named h1702 therein [4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use ![]() |
| Risvutatug rezetecan was progressed to clinical trials to evaluate safety and efficacy as a treatment for advanced solid tumours. It was granted orphan drug designation in Japan in March 2026, to allow treatment of small-cell lung cancer. This decision was based on supportive evidence from the phase I ARTEMIS-001 clinical trial [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05276609 | ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors | Phase 1 Interventional | Hansoh BioMedical R&D Company | The ARTEMIS-001 trial | 1 |
| NCT06498479 | ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 Interventional | Hansoh BioMedical R&D Company | The ARTEMIS-008 trial | |
| NCT06671379 | A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC | Phase 3 Interventional | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | The HERON-Lung01 study | |